tunlametinib   Click here for help

GtoPdb Ligand ID: 11675

Synonyms: Example 9 [WO2013107283A1] | HL-085 | HL085 | Kolupin® (China)
Approved drug
tunlametinib is an approved drug (China (2024))
Compound class: Synthetic organic
Comment: We obtained the chemical structure for tunlametinib from WHO Proposed list 125 (July 2021). This mapped to PubChem CID 71621329. The chemical structure is claimed in Tianjin Binjiang Pharma's patent WO2013107283A1 for activity as a mitogen-activated protein kinase kinase (MEK) inhibitor with potential to treat cancers and inflammation [4]. The name-to-structure was confirmed by published disclosure in September 2023 [2], and MMOA was reported as a MEK1/2 inhibitor..
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 111.72
Molecular weight 490.96
XLogP 3.82
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCCONC(=O)c1cc2scnc2c(c1Nc1ccc(cc1F)I)F
Isomeric SMILES Fc1c(c(cc2c1ncs2)C(=O)NOCCO)Nc1c(cc(cc1)I)F
InChI InChI=1S/C16H12F2IN3O3S/c17-10-5-8(19)1-2-11(10)21-14-9(16(24)22-25-4-3-23)6-12-15(13(14)18)20-7-26-12/h1-2,5-7,21,23H,3-4H2,(H,22,24)
InChI Key UFZJUVFSSINETF-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

Bioactivity Comments
Tunlametinib (example 9) inhibits proliferation of HT29 and A375 cancer cell lines in vitro (IC50 ≤1 nM), and exhibits anti-tumour efficacy in an HT29 and COLO205 tumour xenograft models. No data for inhibition of MEK enzymatic activity is provided in WO2013107283A1 [4].